345 related articles for article (PubMed ID: 20957337)
1. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy.
Ulasov IV; Nandi S; Dey M; Sonabend AM; Lesniak MS
Mol Med; 2011; 17(1-2):103-12. PubMed ID: 20957337
[TBL] [Abstract][Full Text] [Related]
2. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
3. Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy.
Ming J; Sun B; Li Z; Lin L; Meng X; Han B; Wang R; Wu P; Li J; Cai J; Jiang C
Aging (Albany NY); 2017 Apr; 9(4):1233-1247. PubMed ID: 28446712
[TBL] [Abstract][Full Text] [Related]
4. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Short SC; Giampieri S; Worku M; Alcaide-German M; Sioftanos G; Bourne S; Lio KI; Shaked-Rabi M; Martindale C
Neuro Oncol; 2011 May; 13(5):487-99. PubMed ID: 21363882
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P
Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896
[TBL] [Abstract][Full Text] [Related]
6. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
Blough MD; Beauchamp DC; Westgate MR; Kelly JJ; Cairncross JG
J Neurooncol; 2011 Mar; 102(1):1-7. PubMed ID: 20593219
[TBL] [Abstract][Full Text] [Related]
7. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Gilbert CA; Daou MC; Moser RP; Ross AH
Cancer Res; 2010 Sep; 70(17):6870-9. PubMed ID: 20736377
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z
Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma stem cells resistant to temozolomide-induced autophagy.
Fu J; Liu ZG; Liu XM; Chen FR; Shi HL; Pangjesse CS; Ng HK; Chen ZP
Chin Med J (Engl); 2009 Jun; 122(11):1255-9. PubMed ID: 19567133
[TBL] [Abstract][Full Text] [Related]
11. LncRNA-XIST interacts with
Du P; Zhao H; Peng R; Liu Q; Yuan J; Peng G; Liao Y
Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28831025
[TBL] [Abstract][Full Text] [Related]
12. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
13. EZH2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide.
Liang Q; Wang B; Zhang C; Song C; Wang J; Sun W; Jiang L; Lin J
Curr Cancer Drug Targets; 2024; 24(3):328-339. PubMed ID: 37594167
[TBL] [Abstract][Full Text] [Related]
14. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
Hiddingh L; Tannous BA; Teng J; Tops B; Jeuken J; Hulleman E; Boots-Sprenger SH; Vandertop WP; Noske DP; Kaspers GJ; Wesseling P; Wurdinger T
Oncotarget; 2014 Jan; 5(2):363-74. PubMed ID: 24495907
[TBL] [Abstract][Full Text] [Related]
15. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
16. NEO212 Inhibits Migration and Invasion of Glioma Stem Cells.
Marín-Ramos NI; Thein TZ; Cho HY; Swenson SD; Wang W; Schönthal AH; Chen TC; Hofman FM
Mol Cancer Ther; 2018 Mar; 17(3):625-637. PubMed ID: 29440289
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma.
Poon MW; Zhuang JT; Wong ST; Sun S; Zhang XQ; Leung GK
Anticancer Res; 2015 Dec; 35(12):6487-95. PubMed ID: 26637861
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
19. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Chen CC; Taniguchi T; D'Andrea A
J Mol Med (Berl); 2007 May; 85(5):497-509. PubMed ID: 17221219
[TBL] [Abstract][Full Text] [Related]
20. CXCR4-positive subset of glioma is enriched for cancer stem cells.
Zheng X; Xie Q; Li S; Zhang W
Oncol Res; 2011; 19(12):555-61. PubMed ID: 22812188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
